EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Trametinib treatment for early-stage extracranial arteriovenous malformations: A multicenter, prospective, single-arm pilot study

Yi Sun, Hao Gu, Bin Zhang, Xitao Yang, Mingzhe Wen, Xiong Zhao, Xiaojie Yue, Hongyu Zhang, Xindong Fan, Zigang Xu, Lixin Su, Ren Cai

Journal of the American Academy of Dermatology · 2025-11 · 93 (5) · 1261-1267

DOI: 10.1016/j.jaad.2025.07.033 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2025-11. Verfasst von Yi Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Therapy, Multidisciplinary Team of Vascular Anomalies, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University S…. Hauptthemen laut MEDLINE: Arteriovenous Malformations, Protein Kinase Inhibitors, Pyridones, Pyrimidinones. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Rising-Star Program, School of Medicine, Shanghai Jiao Tong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Extracranial arteriovenous malformations (eAVMs) are progressive vascular anomalies for which conventional therapies are rarely curative. Few standard therapies have been developed for early-stage eAVMs. In particular, the efficacy and safety of trametinib for treating early-stage childhood eAVM are unclear. OBJECTIVE: To assess the efficacy and safety of trametinib treatment for early-stage eAVMs over 12 months of treatment. METHOD: Patients with early-stage eAVM received trametinib for at least 12 months. All participants underwent clinical and radiological follow-up, including quantitative (skin temperature, peak arterial velocity, and skin color) and qualitative (digital subtraction angiography) assessments. RESULTS: Therapeutic outcomes of the 26 patients included the following clinical responses: an average skin lesion blanching rate of 53.5%, a decrease in skin temperature of nearly 1 °C, a decrease in peak arterial blood flow velocity of 74%, and 50% of the patients achieving more than 50% devascularization. Patients with somatic KRAS/MAP2K1 mutations had more significant clinical improvement than patients with RASA1/EPHB4 germline mutations did. Trametinib was well tolerated, with most adverse events assessed as grade 1/2. CONCLUSION: This pilot study demonstrates short-term efficacy and safety in the treatment of early-stage eAVMs utilizing trametinib. Further study is needed to evaluate long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arteriovenous MalformationsProtein Kinase InhibitorsPyridonesPyrimidinonesAdolescentChildChild, PreschoolFemaleHumansMaleAngiography, Digital SubtractionMAP Kinase Kinase 1Pilot ProjectsProspective StudiesProto-Oncogene Proteins p21(ras)Treatment Outcome

Stichwörter der Autor:innen

arteriovenous malformationchemotherapyport-wine stainstargeted medicinetrametinibvascular anomalyvascular malformation

Substanzen

MAP Kinase Kinase 1MAP2K1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridonesPyrimidinonestrametinib

Autor:innen und Institutionen

  • Department of Interventional Therapy, Multidisciplinary Team of Vascular Anomalies, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
  • Department of Burn and Plastic Surgery, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, PR China.
  • Department of Dermatology, Beijing Children's Hospital, Capital Medical University, Beijing, PR China.
  • Department of Oral and Maxillofacial Surgery, Stomatology Hospital of Jiamusi University, Jiamusi, PR China.
  • Department of Dermatology, Beijing Children's Hospital, Capital Medical University, Beijing, PR China. Electronic address: zigangxupek@163.com.
  • Department of Interventional Therapy, Multidisciplinary Team of Vascular Anomalies, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. Electronic address: sulixin1975…

Förderung

  • Shanghai Rising-Star Program
  • School of Medicine, Shanghai Jiao Tong University
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Shanghai Lingjun Program

Zitieren

APA

Sun, Y., Gu, H., Zhang, B., Yang, X., Wen, M., Zhao, X., Yue, X., Zhang, H., Fan, X., Xu, Z., Su, L., & Cai, R. (2025). Trametinib treatment for early-stage extracranial arteriovenous malformations: A multicenter, prospective, single-arm pilot study. Journal of the American Academy of Dermatology, 93(5), 1261-1267. https://doi.org/10.1016/j.jaad.2025.07.033

Vancouver

Sun Y, Gu H, Zhang B, Yang X, Wen M, Zhao X, et al. Trametinib treatment for early-stage extracranial arteriovenous malformations: A multicenter, prospective, single-arm pilot study. Journal of the American Academy of Dermatology. 2025;93(5):1261-1267. doi:10.1016/j.jaad.2025.07.033

BibTeX
@article{Sun2025,
  author = {Sun, Yi and Gu, Hao and Zhang, Bin and Yang, Xitao and Wen, Mingzhe and Zhao, Xiong and Yue, Xiaojie and Zhang, Hongyu and Fan, Xindong and Xu, Zigang and Su, Lixin and Cai, Ren},
  title = {Trametinib treatment for early-stage extracranial arteriovenous malformations: A multicenter, prospective, single-arm pilot study},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  volume = {93},
  number = {5},
  pages = {1261--1267},
  doi = {10.1016/j.jaad.2025.07.033}
}
Kostenlos starten →